Alexandre Seillier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alexandre Seillier has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Andrea Giuffrida
Department of Pharmacology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229-3900, USA
6 shared publications Alex A Martinez
Department of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, TX , USA
1 shared publication- Alexander Salazar
Department of Pharmacology, The University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX USA 78229
1 shared publication - Amanda Tristan
Department of Pharmacology, The University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX USA 78229
1 shared publication - Corey Smolik
Department of Physiology, The University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX USA 78229
1 shared publication - Crystal Rock
Department of Biology, Neuroscience Institute, University of Texas at San Antonio, San Antonio, TX, USA
1 shared publication
Latest Publications
- 1 April 2014
- Published by Elsevier in Schizophrenia Research
- Vol. 153, S46
ENDOCANNABINOID-ENHANCING DRUGS REVERSE SOCIAL WITHDRAWAL IN THE PCP RAT MODEL OF SCHIZOPHRENIA
- 1 April 2014
- Published by Elsevier in Schizophrenia Research
- Vol. 153, S46
ENDOCANNABINOID-ENHANCING DRUGS REVERSE SOCIAL WITHDRAWAL IN THE PCP RAT MODEL OF SCHIZOPHRENIA
- 5 April 2013
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 38 (9) , 1816-1824
Phencyclidine-Induced Social Withdrawal Results from Deficient Stimulation of Cannabinoid CB1 Receptors: Implications for Schizophrenia
The neuronal mechanisms underlying social withdrawal, one of the core negative symptoms of schizophrenia, are not well understood. Recent studies suggest an involvement of the endocannabinoid system in the pathophysiology of schizophrenia and, in particular, of negative symptoms. We used biochemical, pharmacological, and behavioral approaches to investigate the role played by the endocannabinoid system in social withdrawal induced by sub-chronic administration of phencyclidine (PCP). Pharmacological enhancement of endocannabinoid levels via systemic administration of URB597, an inhibitor of endocannabinoid degradation, reversed social withdrawal in PCP-treated rats via stimulation of CB1 receptors, but reduced social interaction in control animals through activation of a cannabinoid/vanilloid-sensitive receptor. In addition, the potent CB agonist CP55,940 reversed PCP-induced social withdrawal in a CB1-dependent manner, whereas pharmacological blockade of CB1 receptors by either AM251 or SR141716 reduced the time spent in social interaction in control animals. PCP-induced social withdrawal was accompanied by a decrease of anandamide (AEA) levels in the amygdala and prefrontal cortex, and these deficits were reversed by URB597. As CB1 receptors are predominantly expressed on GABAergic interneurons containing the anxiogenic peptide cholecystokinin (CCK), we also examined whether the PCP-induced social withdrawal resulted from deficient CB1-mediated modulation of CCK transmission. The selective CCK2 antagonist LY225910 blocked both PCP- and AM251-induced social withdrawal, but not URB597 effect in control rats. Taken together, these findings indicate that AEA-mediated activation of CB1 receptors is crucial for social interaction, and that PCP-induced social withdrawal results from deficient endocannabinoid transmission.
- 5 April 2013
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 38 (9) , 1816-1824
Phencyclidine-Induced Social Withdrawal Results from Deficient Stimulation of Cannabinoid CB1 Receptors: Implications for Schizophrenia
The neuronal mechanisms underlying social withdrawal, one of the core negative symptoms of schizophrenia, are not well understood. Recent studies suggest an involvement of the endocannabinoid system in the pathophysiology of schizophrenia and, in particular, of negative symptoms. We used biochemical, pharmacological, and behavioral approaches to investigate the role played by the endocannabinoid system in social withdrawal induced by sub-chronic administration of phencyclidine (PCP). Pharmacological enhancement of endocannabinoid levels via systemic administration of URB597, an inhibitor of endocannabinoid degradation, reversed social withdrawal in PCP-treated rats via stimulation of CB1 receptors, but reduced social interaction in control animals through activation of a cannabinoid/vanilloid-sensitive receptor. In addition, the potent CB agonist CP55,940 reversed PCP-induced social withdrawal in a CB1-dependent manner, whereas pharmacological blockade of CB1 receptors by either AM251 or SR141716 reduced the time spent in social interaction in control animals. PCP-induced social withdrawal was accompanied by a decrease of anandamide (AEA) levels in the amygdala and prefrontal cortex, and these deficits were reversed by URB597. As CB1 receptors are predominantly expressed on GABAergic interneurons containing the anxiogenic peptide cholecystokinin (CCK), we also examined whether the PCP-induced social withdrawal resulted from deficient CB1-mediated modulation of CCK transmission. The selective CCK2 antagonist LY225910 blocked both PCP- and AM251-induced social withdrawal, but not URB597 effect in control rats. Taken together, these findings indicate that AEA-mediated activation of CB1 receptors is crucial for social interaction, and that PCP-induced social withdrawal results from deficient endocannabinoid transmission.
- 1 August 2012
- Published by Elsevier in Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Vol. 38 (2) , 260-269
Acetaminophen differentially enhances social behavior and cortical cannabinoid levels in inbred mice
- 1 August 2012
- Published by Elsevier in Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Vol. 38 (2) , 260-269
Acetaminophen differentially enhances social behavior and cortical cannabinoid levels in inbred mice
- 1 June 2011
- Published by Elsevier in Pharmacology Biochemistry and Behavior
- Vol. 98 (4) , 583-586
Inhibition of fatty acid amide hydrolase modulates anxiety-like behavior in PCP-treated rats
- 1 June 2011
- Published by Elsevier in Pharmacology Biochemistry and Behavior
- Vol. 98 (4) , 583-586
Inhibition of fatty acid amide hydrolase modulates anxiety-like behavior in PCP-treated rats
- 7 December 2009
- Published by Elsevier in Behavioural Brain Research
- Vol. 204 (2) , 410-415
Evaluation of NMDA receptor models of schizophrenia: Divergences in the behavioral effects of sub-chronic PCP and MK-801
- 7 December 2009
- Published by Elsevier in Behavioural Brain Research
- Vol. 204 (2) , 410-415
Evaluation of NMDA receptor models of schizophrenia: Divergences in the behavioral effects of sub-chronic PCP and MK-801
- Open Access
- 17 July 2009
- Published by Oxford University Press (OUP) in International Journal of Neuropsychopharmacology
- Vol. 13 (03) , 373-386
Inhibition of fatty-acid amide hydrolase and CB1 receptor antagonism differentially affect behavioural responses in normal and PCP-treated rats
The ‘cannabinoid hypothesis’ of schizophrenia tulates that over-activity of the endocannabinoid system might contribute to the aetiology of schizophre
- 17 July 2009
- Published by Oxford University Press (OUP) in International Journal of Neuropsychopharmacology
- Vol. 13 (03) , 373-386
Open AccessInhibition of fatty-acid amide hydrolase and CB1 receptor antagonism differentially affect behavioural responses in normal and PCP-treated rats
The ‘cannabinoid hypothesis’ of schizophrenia tulates that over-activity of the endocannabinoid system might contribute to the aetiology of schizophre